Krzysztof Piotr Ratnicki

Dr. Krzysztof Piotr Ratnicki


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 August 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Iwona Gorczyca-GłowackaIwona Gorczyca-Głowacka
Iwona Gorczyca-Głowacka
MKMagdalena Kołomańska
Magdalena Kołomańska
RMRobert Mazurkiewicz
Robert Mazurkiewicz
MNMarcin Niżnik
Marcin Niżnik
KRKrzysztof Piotr Ratnicki
Krzysztof Piotr Ratnicki
LNLukasz Nawacki
Lukasz Nawacki
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is defined by the presence of hepatic steatosis and at least one cardiometabolic risk factor. Differences in the incidence of MASLD between men and women are primarily due to distinct metabolic and cardiovascular profiles. The aim of this observational study was to investigate the prevalence and characteristics of MASLD in men and women. Methods: The study included patients from the Polish Gallstone Surgery Registry diagnosed with MASLD according to current criteria. Results: Among 3419 patients, MASLD was diagnosed in 24.2%. Its prevalence was significantly higher in men (29.8%) than in women (21.9%) (p < 0.0001), with the highest incidence observed in men aged 70–79 (32.1%) and women aged 70–79 (33.3%). MASLD was associated with overweight in individuals aged < 50 years (OR 1.87; 95% CI: 1.11–3.14; p < 0.0186) and in those aged ≥ 50 years (OR 1.99; 95% CI: 1.48–2.68; p < 0.001), as well as with obesity in patients aged < 50 years (OR 6.53; 95% CI: 4.08–10.47; p < 0.001) and in those aged ≥ 50 years (OR 3.9; 95% CI: 2.92–5.22; p < 0.0001). Conclusions: In this study, MASLD was diagnosed more frequently in men than in women, and its incidence showed a positive association with increasing BMI. These findings indicate that excess body weight and sex are key predictors of MASLD, highlighting the need for individualized treatment strategies.

31 July 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
Iwona Gorczyca-GłowackaIwona Gorczyca-Głowacka
Iwona Gorczyca-Głowacka
MKMagdalena Kołomańska
Magdalena Kołomańska
RMRobert Mazurkiewicz
Robert Mazurkiewicz
MNMarcin Niżnik
Marcin Niżnik
KRKrzysztof Piotr Ratnicki
Krzysztof Piotr Ratnicki
LNLukasz Nawacki
Lukasz Nawacki
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is defined by the presence of hepatic steatosis and at least one the cardiometabolic risk factors. Differences in the incidence of MASLD between men and women are primarily due to distinct metabolic and cardiovascular profiles. The aim of this observational study was to investigate the prevalence and characteristics of MASLD in men and women. Methods: The study included patients from The Polish Gallstone Surgery Registry diagnosed with MASLD according to current criteria. Results: Among 3419 patients, MASLD was diagnosed in 24.2%. Its prevalence was significantly higher in man (29.8%) than in women (21.9%) (p< 0.0001), with the highest incidence observed in men aged 70-79 (32.1%) and women aged 70-79 (33.3%). MASLD was associated with overweight in both men (OR 1.60; 95% CI: 1.03–2.48) and women (OR 2.45; 95% CI: 1.80–3.35), as well as with obesity in men (OR 3.44; 95% CI: 2.21–5.34) and women (OR 5.51; 95% CI: 4.10–7.40). Conclusions: In this study, MASLD was diagnosed more frequently in men than in women. The incidence of MASLD increased with age and BMI, with this relationship being more pronounced in women. Therefore, age and excess body weight are key predictors of MASLD, highlighting the need for individualized treatment strategies, regardless of gender.